|Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy|
EA Collisson, A Sadanandam, P Olson, WJ Gibb, M Truitt, S Gu, J Cooc, ...
Nature medicine 17 (4), 500-503, 2011
|A central role for RAF→ MEK→ ERK signaling in the genesis of pancreatic ductal adenocarcinoma|
EA Collisson, CL Trejo, JM Silva, S Gu, JE Korkola, LM Heiser, ...
Cancer discovery 2 (8), 685-693, 2012
|Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections|
MS Draz, BA Fang, P Zhang, Z Hu, S Gu, KC Weng, JW Gray, FF Chen
Theranostics 4 (9), 872, 2014
|Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+ Breast Cancer|
W Ngamcherdtrakul, J Morry, S Gu, DJ Castro, SM Goodyear, ...
Advanced functional materials 25 (18), 2646-2659, 2015
|The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer|
Z Hu, G Huang, A Sadanandam, S Gu, ME Lenburg, M Pai, N Bayani, ...
Breast cancer research 12, 1-15, 2010
|Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis|
J Morry, W Ngamcherdtrakul, S Gu, SM Goodyear, DJ Castro, MM Reda, ...
Biomaterials 66, 41-52, 2015
|Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery|
W Ngamcherdtrakul, T Sangvanich, M Reda, S Gu, D Bejan, W Yantasee
International journal of nanomedicine, 4015-4027, 2018
|Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform|
J Morry, W Ngamcherdtrakul, S Gu, M Reda, DJ Castro, T Sangvanich, ...
Molecular cancer therapeutics 16 (4), 763-772, 2017
|PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer|
M Reda, W Ngamcherdtrakul, S Gu, DS Bejan, N Siriwon, JW Gray, ...
Cancer letters 467, 9-18, 2019
|Therapeutic siRNA for drug-resistant HER2-positive breast cancer|
S Gu, Z Hu, W Ngamcherdtrakul, DJ Castro, J Morry, MM Reda, JW Gray, ...
Oncotarget 7 (12), 14727, 2016
|Current development of targeted oligonucleotide-based cancer therapies: perspective on HER2-positive breast cancer treatment|
W Ngamcherdtrakul, DJ Castro, S Gu, J Morry, M Reda, JW Gray, ...
Cancer treatment reviews 45, 19-29, 2016
|Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment|
S Gu, W Ngamcherdtrakul, M Reda, Z Hu, JW Gray, W Yantasee
PloS one 13 (6), e0198141, 2018
|Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer|
Z Hu, JH Mao, C Curtis, G Huang, S Gu, L Heiser, ME Lenburg, ...
Breast cancer research 18, 1-12, 2016
|Lanthanide-loaded nanoparticles as potential fluorescent and mass probes for high-content protein analysis|
W Ngamcherdtrakul, T Sangvanich, S Goodyear, M Reda, S Gu, ...
Bioengineering 6 (1), 23, 2019
|Abstract 2020: A Systems Analysis of Mitotic Apparatus Inhibitors Defines a Response Network for Breast Cancer.|
Z Hu, J Mao, G Huang, W Kuo, M Lenburg, S Ziyad, J Korkola, N Bayani, ...
Cancer Research 69 (24 Supplement), 2020-2020, 2009
|Abstract 5572: Small molecular inhibitor of centromere-associated protein E (CENP-E), GSK923295A inhibits cell growth in breast cancer cells|
Z Hu, W Kuo, D Das, S Ziyad, S Gu, S Bhattacharya, A Wyrobek, N Wang, ...
Cancer Research 69 (9 Supplement), 5572-5572, 2009
|Nanoparticle Based RNAi Therapeutic to Overcome Intrinsic and Acquired Resistance in HER2+ Breast Cancer|
Oregon Health & Science University, 2018
|4th International Conference on Nanotek & Expo|
M Reda, W Yantasee, W Ngamcherdtrakul, S Gu, J Morry, S Goodyear, ...
|P5. EXPERIMENTAL THERAPEUTICS|
S Gu, S Goodyear, W Ngamcherdtrakul, J Morry, T Sangvanich, D Castro, ...
|Abstract LB-208: Small interfering RNA library screen to identify therapeutic transcription factor.|
Z Hu, S Gu, J Gray, J Rantala
Cancer Research 73 (8_Supplement), LB-208-LB-208, 2013